Skip to main content
. Author manuscript; available in PMC: 2021 Sep 15.
Published in final edited form as: Acc Chem Res. 2020 Aug 12;53(9):1869–1880. doi: 10.1021/acs.accounts.0c00323

Figure 7.

Figure 7.

Nanomedicines for RM-AKI treatment. (a) Specific kidney accumulation of antioxidant nanomedicines facilitates RM-AKI treatment via local ROS scavenging. (b) Rectangular DNA origami nanostructure (Rec-DON) with high renal accumulation treated RM-AKI more efficiently than the clinically used drug NAC. Treatment dose of M13 and Rec-DON: 0.5 mg/kg; H-NAC: high-dose NAC (210 mg/kg); L-NAC: low-dose NAC (0.5 mg/kg) (c) Ultrasmall melanin nanoparticles outperformed clinical contrast agents for MRI imaging of kidney injury, and intrinsic antioxidant property enabled a theranostic approach. Panel a and b adapted with permission from Ref.1. Copyright (2018) Nature Publishing Group. Panel c adapted with permission from Ref.24. Copyright (2019) John Wiley and Sons.